ReviewLasers in medical science2026
Machine learning enhanced optical spectroscopy for breast cancer diagnosis: A review.
Review in Lasers in medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This literature review examines the transformative role of machine learning (ML) and deep learning (DL) in enhancing optical spectroscopy for breast cancer diagnosis. By synthesizing advancements from peer-reviewed studies (2015-2025), we evaluate how ML/DL integration improves the detection of malignancy-associated biochemical changes, enabling noninvasive, rapid, and accurate differentiation between healthy and cancerous tissues. This review highlights key spectroscopic modalities, such as Raman, fluorescence, diffusive optical spectroscopy (DOS), and photoacoustic spectroscopy (PAS), and their integration with AI-driven models, such as convolutional neural networks (CNNs), support vector machines (SVMs), and logistic regression. These techniques achieve diagnostic accuracies of up to 94% in subtype classification (e.g., luminal A, HER2-positive) by analyzing spectral biomarkers such as hemoglobin, lipids, and collagen. Challenges such as data variability, model interpretability, and clinical integration barriers are critically assessed. These findings underscore the potential of ML/DL-enhanced spectroscopy to standardize diagnostics, reduce unnecessary biopsies, and personalize treatment monitoring. Future directions emphasize the need for explainable AI (XAI), multimodal data fusion, and large-scale, diverse datasets to bridge translational gaps. By addressing technical, ethical, and regulatory hurdles, this integration promises to advance early detection, improve clinical outcomes, and reshape precision oncology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.